A Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs VL 2397 (Primary)
- Indications Aspergillosis
- Focus Registrational; Therapeutic Use
- Sponsors Vical
- 05 Oct 2017 According a Vical media release, antifungal VL-2397 is eligible for limited use indication approval by FDA based on this Phase II efficacy trial.
- 05 Jun 2017 According a Vical media release, company is planning to initiate this trial in fourth quarter of 2017.
- 18 Nov 2016 New trial record